Biotech News

TherapeuticsMD Announces Second Quarter 2024 Financial Results

TherapeuticsMD (TXMD)TherapeuticsMDEarnings

BOCA RATON, Fla. --(BUSINESS WIRE)--Aug. 12, 2024-- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, 2024 .

Related news

TherapeuticsMD

Pharmaceutical Royalty Company TherapeuticsMD owns rights to royalties and license revenue from women’s health pharmaceutical products rather than operating a broad internal commercial organization. Royalty Portfolio Model Revenue is primarily tied to products licensed under the Mayne agreement, giving TherapeuticsMD exposure to partner...

Recent company news

Stock data

Close
2.09 USD
Market cap
23.61M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States